RFG Advisory LLC Sells 559 Shares of Danaher Co. (NYSE:DHR)

RFG Advisory LLC reduced its position in shares of Danaher Co. (NYSE:DHR) by 8.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,416 shares of the conglomerate’s stock after selling 559 shares during the quarter. RFG Advisory LLC’s holdings in Danaher were worth $1,473,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. acquired a new stake in Danaher in the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher in the 3rd quarter valued at $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on DHR. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Barclays lowered their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research note on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Stock Performance

Shares of NYSE:DHR opened at $245.95 on Friday. The company’s 50 day simple moving average is $235.33 and its 200 day simple moving average is $253.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The stock has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.